Compare VIR & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | ORC |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2019 | 2011 |
| Metric | VIR | ORC |
|---|---|---|
| Price | $11.79 | $5.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $20.78 | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 5.1M |
| Earning Date | 11-04-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 23.48% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,556,000.00 | N/A |
| Revenue This Year | $257.66 | $35.95 |
| Revenue Next Year | N/A | $11.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.82 | $5.22 |
| 52 Week High | $11.94 | $8.40 |
| Indicator | VIR | ORC |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 15.23 |
| Support Level | $8.43 | N/A |
| Resistance Level | $11.77 | $6.93 |
| Average True Range (ATR) | 0.57 | 0.16 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 92.24 | 5.12 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.